# 5-Year Safety Study of Pimecrolimus Cream 1% in Infants 3 - 12 Months of Age With Mild to Moderate Atopic Dermatitis

> **NCT00120523** · PHASE3 · COMPLETED · sponsor: **MEDA Pharma GmbH & Co. KG** · enrollment: 2418 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** Pimecrolimus
- **DRUG:** Topical corticosteroids

## Key facts

- **NCT ID:** NCT00120523
- **Lead sponsor:** MEDA Pharma GmbH & Co. KG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-04
- **Primary completion:** 2010-10
- **Final completion:** 2010-10
- **Target enrollment:** 2418 (ACTUAL)
- **Last updated:** 2022-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00120523

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00120523, "5-Year Safety Study of Pimecrolimus Cream 1% in Infants 3 - 12 Months of Age With Mild to Moderate Atopic Dermatitis". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT00120523. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*